Your browser doesn't support javascript.
loading
Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
Li, Xiao-Lan; Li, Guo-Hua; Fu, Juan; Fu, Ya-Wen; Zhang, Lu; Chen, Wanqiu; Arakaki, Cameron; Zhang, Jian-Ping; Wen, Wei; Zhao, Mei; Chen, Weisheng V; Botimer, Gary D; Baylink, David; Aranda, Leslie; Choi, Hannah; Bechar, Rachel; Talbot, Prue; Sun, Chang-Kai; Cheng, Tao; Zhang, Xiao-Bing.
Afiliação
  • Li XL; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Li GH; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Fu J; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Fu YW; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Zhang L; Liaoning Provincial Key Laboratory of Cerebral Diseases, Institute for Brain Disorders, Dalian Medical University, Dalian 116044, China.
  • Chen W; Department of Obstetrics and Gynecology, the First Affiliated Hospital of Dalian Medical University, Dalian 116044, China.
  • Arakaki C; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Zhang JP; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Wen W; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Zhao M; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Chen WV; Department of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
  • Botimer GD; Department of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
  • Baylink D; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Aranda L; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Choi H; CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China.
  • Bechar R; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Talbot P; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Sun CK; State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
  • Cheng T; Institute of Hematology and Blood Disease Hospital, Tianjin 300020, China.
  • Zhang XB; Leveragen, Inc., Cambridge, MA 01605, USA.
Nucleic Acids Res ; 46(19): 10195-10215, 2018 11 02.
Article em En | MEDLINE | ID: mdl-30239926
ABSTRACT
Genome editing of human induced pluripotent stem cells (iPSCs) is instrumental for functional genomics, disease modeling, and regenerative medicine. However, low editing efficiency has hampered the applications of CRISPR-Cas9 technology in creating knockin (KI) or knockout (KO) iPSC lines, which is largely due to massive cell death after electroporation with editing plasmids. Here, we report that the transient delivery of BCL-XL increases iPSC survival by ∼10-fold after plasmid transfection, leading to a 20- to 100-fold increase in homology-directed repair (HDR) KI efficiency and a 5-fold increase in non-homologous end joining (NHEJ) KO efficiency. Treatment with a BCL inhibitor ABT-263 further improves HDR efficiency by 70% and KO efficiency by 40%. The increased genome editing efficiency is attributed to higher expressions of Cas9 and sgRNA in surviving cells after electroporation. HDR or NHEJ efficiency reaches 95% with dual editing followed by selection of cells with HDR insertion of a selective gene. Moreover, KO efficiency of 100% can be achieved in a bulk population of cells with biallelic HDR KO followed by double selection, abrogating the necessity for single cell cloning. Taken together, these simple yet highly efficient editing strategies provide useful tools for applications ranging from manipulating human iPSC genomes to creating gene-modified animal models.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína bcl-X / Células-Tronco Pluripotentes Induzidas / Sistemas CRISPR-Cas / Edição de Genes Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína bcl-X / Células-Tronco Pluripotentes Induzidas / Sistemas CRISPR-Cas / Edição de Genes Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article